Skip to main content
SpringerLink
Log in

Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The objective of the study was to produce rapidly dissolving formulations of the poorly water-soluble drug repaglinide using an innovative new technology, ultra-rapid freezing (URF), and to investigate the influence of excipient type on repaglinide stability. Repaglinide compositions containing different types and levels of excipients and different drug potencies (50%–86%) were produced by the URF technology. Repaglinide/excipient solutions were frozen on a cryogenic substrate, collected, and lyophilized to form a dry powder. Surfactants, including sodium dodecyl sulfate, and alkalizing agents such as diethanolamine (DEA) and tromethamine (TRIS) were incorporated into the compositions. Forced degradation of repaglinide was conducted under stressed conditions (eg, elevated temperature, exposure to peroxide) to determine the stability of the drug in such environments. The solubility of repaglinide increased as a function of increasing pH; therefore, incorporation of an alkalizing agent into the URF formulations increased the drug's solubility. Drug instability resulted when the drug was exposed to pH values above 9.0. URF formulations containing alkalizing agents showed no degradation or spontaneous recrystallization in the formulation, indicating that increased stability was afforded by processing. URF processing created nanostructured drug/excipient particles with higher dissolution rates than were achieved for unprocessed drug. Alkalizing agents such as TRIS and DEA, present at levels of 25% to 33% wt/wt in the formulations, did not cause degradation of the drug when processed using URF. URF processing, therefore, yielded fast-dissolving formulations that were physically and chemically stable, resistant to alkali degradation or spontaneous recrystallization in the formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Amidon GL. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.Pharm Res. 1995;12:413–420.

    Article  CAS  Google Scholar 

  2. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water soluble drugs.Eur J Pharm Sci. 2000;11:S73-S80.

    Article  CAS  Google Scholar 

  3. Hu JH, Johnston KP, Williams RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs.Drug Dev Ind Pharm. 2004;30:233–245.

    Article  Google Scholar 

  4. Hu JH, Johnston KP, Williams RO. Spray-freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems.Eur J Pharm Sci. 2003;20:295–303.

    Article  CAS  Google Scholar 

  5. Hu JH, Johnston KP, Williams RO. Rapid dissolving high potency danazol powders produced by spray freezing into liquid process.Int J Pharm. 2004;271:145–154.

    Article  CAS  Google Scholar 

  6. Yu ZS, Rogers TL, Hu JH, Johnston KP, Williams RO. Preparation and characterization of microparticles containing peptide produced by a novel process: spray-freezing into liquid.Eur J Pharm Biopharm. 2002;54:221–228.

    Article  CAS  Google Scholar 

  7. Rogers TL, Nelson AC, Hu JH, et al. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid.Eur J Pharm Biopharm. 2002;54:271–280.

    Article  CAS  Google Scholar 

  8. Rogers TL, Johnston KP, Williams RO. Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid carbon dioxide and cryogenic spray-freezing technologies.Drug Dev Ind Pharm. 2001;27:1003–1015.

    Article  CAS  Google Scholar 

  9. Vaughn JM, Gao X, Yacaman JM, Johnston KP, Williams RO. Comparison of powder produced by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid (SFL) technologies using Z-contrast STEM and complimentary techniques.Eur J Pharm Biopharm. 2005;60:81–89.

    Article  CAS  Google Scholar 

  10. Etzler FM, Sanderson MS. Particle size analysis: a comparative study of various methods.Part Part Syst Charact. 1995;12:217–224.

    Article  CAS  Google Scholar 

  11. Waltersson JO, Lundgren P. The effect of mechanical comminution on drug stability.Acta Pharm Suec. 1985;22:291–300.

    CAS  Google Scholar 

  12. Leuenberger H. Spray freeze drying: the process of choice for low water soluble drugs?J Nanoparticle Res. 2002;4:111–119.

    Article  CAS  Google Scholar 

  13. Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC. Protein inhalation powders: spray drying vs. spray freeze drying.Pharm Res. 1999;16:249–254.

    Article  CAS  Google Scholar 

  14. Costantino HR, Firouzabadian L, Hogeland K, et al. Protein spray freeze drying. Effect of atomization conditions on particle size and stability.Pharm Res. 2000;17:1374–1383.

    Article  CAS  Google Scholar 

  15. Evans JC, Scherzer BD, Tocco CD. Preparation of nanostructured particles of poorly water soluble drugs via a novel ultra-rapid freezing technology. In: Svenson S, ed.Polymeric Drug Delivery Volume II—Polymeric Matrices and Drug Particle Engineering. New York, NY: American Chemical Society; 2004:2048–2057.

    Google Scholar 

  16. Hall RS, Board SJ, Clare AJ, Duffey RB, Playle TS, Poole DH. Inverse Leidenfrost phenomenon.Nature. 1969;224:266–267.

    Article  CAS  Google Scholar 

  17. Gottfried BS, Lee CJ, Bell KJ. The Leidenfrost phenomenon: film boiling of liquid droplets.Int J Heat Mass Transfer. 1966;9:1167–1187.

    Article  CAS  Google Scholar 

  18. Culy C, Jarvis B. Repaglinide, a review of its therapeutic use in Type 2 diabetes mellitus.Drugs. 2001;61:1625–1660.

    Article  CAS  Google Scholar 

  19. Malaisse W. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies.Eur J Clin Invest. 1999;29:21–29.

    Article  CAS  Google Scholar 

  20. Landgraf R, Frank M, Bauer C, Dieken M. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type II diabetes.Int J Obes. 2000;24:S38-S44.

    Article  Google Scholar 

  21. Wang FEI. Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas.Formulary. 1998;33:article 5.

    Google Scholar 

  22. Higuchi T, Connors K. Phase solubility diagram.Adv Anal Chem Instrum. 1965;4:117–212.

    CAS  Google Scholar 

  23. Gandhimathi M, Ravi T, Renu S. Determination of repaglinide in pharmaceutical formulations by HPLC and UV detection.Anal Sci. 2003;19:1675–1677.

    Article  CAS  Google Scholar 

  24. Krishna Reddy KVSR, Babu J, Mathad V, et al. Impurity profile study of repaglinide.J Pharm Biomed Anal. 2003;32:461–467.

    Article  Google Scholar 

  25. US Food and Drug Administration. Stability Testing: Drug substance stress testing. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; February, 6, 2003; Rockville, MD, Rockville, MD: US Food and Drug Administration; 2003.

  26. Yamashita K, Nakate T, Okimoto K, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus.Int J Pharm. 2003;267:79–91.

    Article  CAS  Google Scholar 

  27. Grell W, Hurnaus R, Griss G, et al. Repaglinide and related hypoglycemic benzoic acid derivatives.J Med Chem. 1998;41: 5219–5246.

    Article  Google Scholar 

  28. Nakagaki M, Yokoyama S. Acid catalyzed hydrolysis of sodium dodecyl sulfate.J Pharm Sci. 1985;74:1047–1052.

    Article  CAS  Google Scholar 

  29. Patel KC, Banker GS, DeKay HG. Anionic and cationic wetting agents in a hydrophilic ointment-base, I: choice of wetting agents.J Pharm Sci. 1961;50:294–300.

    Article  CAS  Google Scholar 

  30. Newton JM, Rowley G, Tornblom JFV. Effect of additives on the release of drug from hard gelatin capsules.J Pharm Pharmacol. 1971;23:452–453.

    CAS  Google Scholar 

  31. Newton JM, Razzo FN. Interaction of formulation factors and dissolution fluid and the in vitro release of drug from hard gelatin capsules.J Pharm Pharmacol. 1975;27:78P.

    Google Scholar 

  32. Valsami G, Dokoumetzidis A, Macheras P. Modeling of supersaturated dissolution data.Int J Pharm. 1999;181:153–157.

    Article  CAS  Google Scholar 

  33. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals?Pharm Res. 2000;17:397–404.

    Article  CAS  Google Scholar 

  34. Hancock BC, Zograffi G. Characteristics and significance of the amorphous state in pharmaceutical systems.J Pharm Sci. 1997;86:1–12.

    Article  CAS  Google Scholar 

  35. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate.Int J Pharm. 2000;193:231–237.

    Article  CAS  Google Scholar 

  36. Gilbert JC, Hadgraft J, Bye A, Brookes LG. Drug release from Pluronic F-127 gels.Int J Pharm. 1986;32:223–228.

    Article  CAS  Google Scholar 

  37. Couarraze G, Leclere B, Conrath G, Falson-Rieg F, Puisieux F. Diffusion of a dispersed solute in a polymeric matrix.Int J Pharm. 1989;56:197–206.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, University of Texas at Austin, 78712, Austin, TX

    Troy Purvis & Robert O. Williams

  2. Department of Chemical Engineering, University of Texas at Austin, 78712, Austin, TX

    Michal E. Mattucci, M. Todd Crisp & Keith P. Johnston

Authors
  1. Troy Purvis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michal E. Mattucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Todd Crisp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keith P. Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert O. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert O. Williams.

Additional information

Published: July 20, 2007

Rights and permissions

Reprints and permissions

About this article

Cite this article

Purvis, T., Mattucci, M.E., Crisp, M.T. et al. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS PharmSciTech 8, 58 (2007). https://doi.org/10.1208/pt0803058

Download citation

  • Received:

  • Revised:

  • Accepted:

  • DOI: https://doi.org/10.1208/pt0803058

Keywords

Search

Navigation